The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer
Abstract
Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is a widely studied lncRNA in cancer. Although dispensable for normal physiology, MALAT1 is important for cancer-related pathways regulation. It is localized in the nuclear speckles periphery along with centrally located pre-RNA splicing factors. MALAT1 associated cancer signaling pathways include MAPK/ERK, PI3K/AKT, β-catenin/Wnt, Hippo, VEGF, YAP, etc. Molecular tools such as immunoprecipitation, RNA pull-down, reporter assay, Northern blotting, microarray, and q-RT-PCR has been used to elucidate MALAT1's function in cancer pathogenesis. MALAT1 can regulate multiple steps in the development of tumours. The diagnostic and prognostic significance of MALAT1 has been demonstrated for cancers of the breast, cervix, colorectum, gallbladder, lung, ovary, pancreas, prostate, glioma, hepatocellular carcinoma, and multiple myeloma. MALAT1 has also emerged as a novel therapeutic target for solid as well as hematological malignancies. In experimental models, siRNA and antisense oligonucleotide (ASO) based strategy has been used for targeting MALAT1. The lncRNA has also been targeted for the chemosensitization and radiosensitization of cancer cells. However, most studies have been performed in preclinical models. How the cross-talk of MALAT1 with other signaling pathways affect cancer pathogenesis is the focus of this article. The diagnostic, prognostic, and therapeutic significance of MALAT1 in multiple cancer types are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
6 retracted
Jin, D., Guo, J., Wu, Y., Du, J., Yang, L., Wang, X., Di, W., Hu, B., An, J., Kong, L., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0830-6 · Cited by 501
RetractedJi, Q., Liu, X., Fu, X., Zhang, L., Sui, H., Zhou, L., Sun, J., Cai, J., Qin, J., Ren, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078700 · Cited by 354
RetractedSun, Z., Ou, C., Liu, J., Chen, C., Zhou, Q., Yang, S., Li, G., Wang, G., Song, J., Li, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0628-y · Cited by 209
RetractedJi, Q., Cai, G., Liu, X., Zhang, Y., Wang, Y., Zhou, L., Sui, H. X., & Li, Q. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1598-x · Cited by 114
RetractedZhang, X., He, X., Liu, Y., Zhang, H., Chen, H., Guo, S., & Liang, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.07.005 · Cited by 97
RetractedGu, Y., Xiao, X., & Yang, S. (2017) · Oncotarget · doi:10.18632/oncotarget.21957 · Cited by 64
RetractedEvolution and Functions of Long Noncoding RNAs
Ponting, C. P., Oliver, P. L., & Reik, W. (2009) · Cell · doi:10.1016/j.cell.2009.02.006 · Cited by 4,208
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201
Tripathi, V., Ellis, J. D., Shen, Z., Song, D. Y., Pan, Q., Watt, A. T., Freier, S. M., Bennett, C. F., Sharma, A., Bubulya, P. A., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.08.011 · Cited by 2,219
Ji, P., Diederichs, S., Wang, W., Böing, S., Metzger, R., Schneider, P. M., Tidow, N., Brandt, B., Buerger, H., Bulk, E., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206928 · Cited by 2,189
The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
Gutschner, T., Hämmerle, M., Eißmann, M., Hsu, J., Kim, Y., Hung, G., Revenko, A., Arun, G., Stentrup, M., Groß, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2850 · Cited by 1,415
Revisiting the hallmarks of cancer.
Fouad, Y. A., & Aanei, C. M. (2017) · Europe PMC (PubMed Central) · Cited by 1,245
Long noncoding RNA MALAT1 suppresses breast cancer metastasis
Kim, J., Piao, H.-L., Kim, B.-J., Yao, F., Han, Z., Wang, Y., Xiao, Z., Siverly, A. N., Lawhon, S. E., Ton, B. N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0252-3 · Cited by 771
A long nuclear‐retained non‐coding RNA regulates synaptogenesis by modulating gene expression
Bernard, D., Prasanth, K. V., Tripathi, V., Colasse, S., Nakamura, T., Xuan, Z., Zhang, M. Q., Sedel, F., Jourdren, L., Coulpier, F., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.199 · Cited by 735
3′ End Processing of a Long Nuclear-Retained Noncoding RNA Yields a tRNA-like Cytoplasmic RNA
Wilusz, J. E., Freier, S. M., & Spector, D. L. (2008) · Cell · doi:10.1016/j.cell.2008.10.012 · Cited by 720
The Long Noncoding RNAs NEAT1 and MALAT1 Bind Active Chromatin Sites
West, J. A., Davis, C. P., Sunwoo, H., Simon, M. D., Sadreyev, R. I., Wang, P. I., Tolstorukov, M. Y., & Kingston, R. E. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.012 · Cited by 709
Genome-wide analysis of long noncoding RNA stability
Clark, M. B., Johnston, R. L., Inostroza-Ponta, M., Fox, A. H., Fortini, E., Moscato, P., Dinger, M. E., & Mattick, J. S. (2012) · Genome Research · doi:10.1101/gr.131037.111 · Cited by 593
Nuclear Long Noncoding RNAs: Key Regulators of Gene Expression
Sun, Q., Hao, Q., & Prasanth, K. V. (2018) · Trends in Genetics · doi:10.1016/j.tig.2017.11.005 · Cited by 565
Hirata, H., Hinoda, Y., Shahryari, V., Deng, G., Nakajima, K., Tabatabai, Z. L., Ishii, N., & Dahiya, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2931 · Cited by 551
Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets
Chandra Gupta, S., & Nandan Tripathi, Y. (2017) · International Journal of Cancer · doi:10.1002/ijc.30546 · Cited by 527
The long noncoding RNA Malat1: Its physiological and pathophysiological functions
Zhang, X., Hamblin, M. H., & Yin, K.-J. (2017) · RNA Biology · doi:10.1080/15476286.2017.1358347 · Cited by 482
TGF-β–Induced Upregulation of malat1 Promotes Bladder Cancer Metastasis by Associating with suz12
Fan, Y., Shen, B., Tan, M., Mu, X., Qin, Y., Zhang, F., & Liu, Y. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1455 · Cited by 410
Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development
Eißmann, M., Gutschner, T., Hämmerle, M., Günther, S., Caudron-Herger, M., Groß, M., Schirmacher, P., Rippe, K., Braun, T., Zörnig, M., et al. (2012) · RNA Biology · doi:10.4161/rna.21089 · Cited by 395
Puthanveetil, P., Chen, S., Feng, B., Gautam, A., & Chakrabarti, S. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12576 · Cited by 363
Ying, L., Chen, Q., Wang, Y., Zhou, Z., Huang, Y., & Qiu, F. (2012) · Molecular BioSystems · doi:10.1039/c2mb25070e · Cited by 344
YiRen, H., YingCong, Y., Sunwu, Y., Keqin, L., Xiaochun, T., Senrui, C., Ende, C., XiZhou, L., & Yanfan, C. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0743-3 · Cited by 337
Malakar, P., Shilo, A., Mogilevsky, A., Stein, I., Pikarsky, E., Nevo, Y., Benyamini, H., Elgavish, S., Zong, X., Prasanth, K. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1508 · Cited by 317
Dong, Y., Liang, G., Yuan, B., Yang, C., Gao, R., & Zhou, X. (2015) · Tumor Biology · doi:10.1007/s13277-014-2631-4 · Cited by 313
Fei, J., Jadaliha, M., Harmon, T. S., Li, I. T. S., Hua, B., Hao, Q., Holehouse, A. S., Reyer, M., Sun, Q., Freier, S. M., et al. (2017) · Journal of Cell Science · doi:10.1242/jcs.206854 · Cited by 295
Structural insights into the stabilization of MALAT1 noncoding RNA by a bipartite triple helix
Brown, J. A., Bulkley, D., Wang, J., Valenstein, M. L., Yario, T. A., Steitz, T. A., & Steitz, J. A. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2844 · Cited by 290
MALAT1 Long Non-Coding RNA: Functional Implications
Arun, G., Aggarwal, D., & Spector, D. L. (2020) · Non-Coding RNA · doi:10.3390/ncrna6020022 · Cited by 276
MALAT1: a potential biomarker in cancer
Li, Z.-X., Zhu, Q.-N., Zhang, H.-B., Hu, Y., Wang, G., & Zhu, Y.-S. (2018) · Cancer Management and Research · doi:10.2147/cmar.s169406 · Cited by 265
Amodio, N., Stamato, M. A., Juli, G., Morelli, E., Fulciniti, M., Manzoni, M., Taiana, E., Agnelli, L., Cantafio, M. E. G., Romeo, E., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0067-3 · Cited by 260
Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., Yang, Y., & Wang, C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0591 · Cited by 244
Guo, F., Li, Y., Liu, Y., Wang, J., Li, Y., & Li, G. (2010) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmq008 · Cited by 237
Miyagawa, R., Tano, K., Mizuno, R., Nakamura, Y., Ijiri, K., Rakwal, R., Shibato, J., Masuo, Y., Mayeda, A., Hirose, T., et al. (2012) · RNA · doi:10.1261/rna.028639.111 · Cited by 237
Li, Q., Lai, Q., He, C., Fang, Y., Yan, Q., Zhang, Y., Wang, X., Gu, C., Wang, Y., Ye, L., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1330-9 · Cited by 232
Long non-coding RNAs are emerging targets of phytochemicals for cancer and other chronic diseases
Mishra, S., Verma, S. S., Rai, V., Awasthee, N., Chava, S., Hui, K. M., Kumar, A. P., Challagundla, K. B., Sethi, G., & Gupta, S. C. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03053-0 · Cited by 226
Self-citationThe Role of microRNAs, Long Non-coding RNAs, and Circular RNAs in Cervical Cancer
Tornesello, M. L., Faraonio, R., Buonaguro, L., Annunziata, C., Starita, N., Cerasuolo, A., Pezzuto, F., Tornesello, A. L., & Buonaguro, F. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00150 · Cited by 214
Li, P., Zhang, X., Wang, H., Wang, L., Liu, T., Du, L., Yang, Y., & Wang, C. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1028 · Cited by 193
Wu, X.-S., Wang, X.-A., Wu, W.-G., Hu, Y.-P., Li, M.-L., Ding, Q., Weng, H., Shu, Y.-J., Liu, T.-Y., Jiang, L., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28584 · Cited by 187
Qiu, J.-J., Lin, X.-J., Tang, X.-Y., Zheng, T.-T., Lin, Y.-Y., & Hua, K.-Q. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.28048 · Cited by 186
Guo, D., Ma, J., Yan, L., Li, T., Li, Z., Han, X., & Shui, S. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000480337 · Cited by 170
Gong, N., Teng, X., Li, J., & Liang, X.-J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b18288 · Cited by 169
MALAT1 promotes cell proliferation in gastric cancer by recruiting SF2/ASF
Wang, J., Su, L., Chen, X., Li, P., Cai, Q., Yu, B., Liu, B., Wu, W., & Zhu, Z. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.04.007 · Cited by 164
Jadaliha, M., Zong, X., Malakar, P., Ray, T., Singh, D. K., Freier, S. M., Jensen, T., Prasanth, S. G., Karni, R., Ray, P. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9622 · Cited by 162
Xu, J., Xiao, Y., Liu, B., Pan, S., Liu, Q., Shan, Y., Li, S., Qi, Y., Huang, Y., & Li, J. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01562-6 · Cited by 159
MALAT1: An Epigenetic Regulator of Inflammation in Diabetic Retinopathy
Biswas, S., Thomas, A. A., Chen, S., Aref-Eshghi, E., Feng, B., Gonder, J., Sadikovic, B., & Chakrabarti, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-24907-w · Cited by 158
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma
Hu, Y., Lin, J., Hua, F., Fang, J., Li, C., Chen, W., Liu, S., Ondrejka, S. L., Gong, Z., Reu, F. J., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0104-2 · Cited by 156
Long non-coding RNAs and nuclear factor-κB crosstalk in cancer and other human diseases
Gupta, S. C., Awasthee, N., Rai, V., Chava, S. P., Gunda, V., & Challagundla, K. B. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188316 · Cited by 148
Self-citationLi, Q., Zhang, C., Chen, R., Xiong, H., Qiu, F., Liu, S., Zhang, M., Wang, F., Wang, Y., Zhou, X., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.09.019 · Cited by 146
Wang, R., Sun, Y., Li, L., Niu, Y., Lin, W.-Y., Lin, C.-Y., Antonarakis, E. S., Luo, J., Yeh, S., & Chang, C. (2017) · European Urology · doi:10.1016/j.eururo.2017.04.005 · Cited by 141
Long Noncoding RNA MALAT1 and Regulation of the Antioxidant Defense System in Diabetic Retinopathy
Radhakrishnan, R., & Kowluru, R. A. (2020) · Diabetes · doi:10.2337/db20-0375 · Cited by 139
Latorre, E., Carelli, S., Raimondi, I., D’Agostino, V., Castiglioni, I., Zucal, C., Moro, G. P., Luciani, A., Ghilardi, G., Monti, E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2018 · Cited by 133
Prognostic significance of drug-regulated genes in high-grade osteosarcoma
Fellenberg, J., Bernd, L., Delling, G., Witte, D., & Zahlten‐Hinguranage, A. (2007) · Modern Pathology · doi:10.1038/modpathol.3800937 · Cited by 131
Luan, W., Li, L., Shi, Y., Bu, X., Xia, Y. F., Wang, J., Djangmah, H. S., Liu, X., You, Y., & Xu, B. (2016) · Oncotarget · doi:10.18632/oncotarget.11564 · Cited by 131
Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide
Kim, S. S., Harford, J. B., Moghe, M., Rait, A. S., Pirollo, K. F., & Chang, E. H. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1221 · Cited by 131
Gordon, M. A., Babbs, B. L., Cochrane, D. R., Bitler, B. G., & Richer, J. K. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22919 · Cited by 129
Wang, Y., Zhang, Y., Yang, T., Zhao, W. G., Wang, N., Li, P., Zeng, X., & Zhang, W. (2017) · Oncotarget · doi:10.18632/oncotarget.19727 · Cited by 124
Zhuang, M., Zhao, S., Jiang, Z., Wang, S., Sun, P., Quan, J., Yan, D., & Wang, X. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.049 · Cited by 123
Li, X., Song, Y., Liu, F., Liu, D., Miao, H., Ren, J., Xu, J., Ding, L., Hu, Y., Wang, Z., et al. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25927 · Cited by 122
Yu, W., Ding, J., He, M., Chen, Y., Wang, R., Han, Z., Xing, E. Z., Zhang, C., & Yeh, S. (2018) · Oncogene · doi:10.1038/s41388-018-0463-1 · Cited by 117
Cao, S., Wang, Y., Li, J., Lv, M., Niu, H., & Tian, Y. (2016) · PubMed · Cited by 115
Imaging-based pooled CRISPR screening reveals regulators of lncRNA localization
Wang, C., Lu, T., Emanuel, G., Babcock, H. P., & Zhuang, X. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903808116 · Cited by 111
Blocking lncRNA MALAT1/miR-199a/ZHX1 Axis Inhibits Glioblastoma Proliferation and Progression
Liao, K., Lin, Y., Gao, W., Xiao, Z., Medina, R., Dmitriev, P., Cui, J., Zhuang, Z., Zhao, X., Qiu, Y., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.09.005 · Cited by 109
Lu, X., Chen, D., Yang, F., & Xing, N. (2020) · Cancer Management and Research · doi:10.2147/cmar.s241093 · Cited by 104
Duan, W., Du, L., Jiang, X., Wang, R., Yan, S., Xie, Y., Yan, K., Wang, Q., Wang, L., Zhang, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12880 · Cited by 101
Huang, S., Zhang, L., Song, J., Wang, Z., Huang, X., Guo, Z., Chen, F., & Zhao, X. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27117 · Cited by 100
Xia, C., Liang, S., He, Z., Zhu, X., Chen, R., & Chen, J. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.027 · Cited by 98
Si, Y., Yang, Z., Ge, Q.-X., Yu, L., Yao, M., Sun, X.-F., Ren, Z., & Ding, C. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0175-8 · Cited by 97
Wang, Y., Wu, C., Zhang, C., Li, Z., Zhu, T., Chen, J., Ren, Y. T., Wang, X., Zhang, L., & Zhou, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.009 · Cited by 94
Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma
Voce, D. J., Bernal, G. M., Wu, L., Crawley, C. D., Zhang, W., Mansour, N. M., Cahill, K. E., Szymura, S. J., Uppal, A., Raleigh, D. R., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2170 · Cited by 94
IL-8 Secreted from M2 Macrophages Promoted Prostate Tumorigenesis via STAT3/MALAT1 Pathway
Zheng, T., Ma, G., Tang, M., Li, Z., & Xu, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010098 · Cited by 89
Bai, L., Wang, A., Zhang, Y., Xu, X., & Zhang, X. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.03.014 · Cited by 87
Natural antisense RNA promotes 3′ end processing and maturation of MALAT1 lncRNA
Zong, X., Nakagawa, S., Freier, S. M., Fei, J., Ha, T., Prasanth, S. G., & Prasanth, K. V. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw047 · Cited by 86
Kwok, Z. H., Roche, V., Chew, X. H., Fadieieva, A., & Tay, Y. (2018) · International Journal of Cancer · doi:10.1002/ijc.31386 · Cited by 86
Tao, F., Tian, X., Ruan, S., Shen, M., & Zhang, Z. (2018) · The FASEB Journal · doi:10.1096/fj.201800495rr · Cited by 86
LncRNA-MALAT1 regulates proliferation and apoptosis of ovarian cancer cells by targeting miR-503-5p
Sun, Q., Li, Q., & Xie, F. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214689 · Cited by 84
Wu, S., Sun, H., Wang, Y., Yang, X., Meng, Q., Yang, H., Zhu, H., Tang, W., Li, X., Aschner, M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0773 · Cited by 83
Liu, N., Feng, S., Li, H., Chen, X., Bai, S., & Liu, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03127-8 · Cited by 83
Peng, N., He, J., Li, J., Huang, H., Huang, W., Liao, Y., & Zhu, S. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01231-w · Cited by 83
Zheng, L.-H., Zhang, Y., Fu, Y., Gong, H., Guo, J., Wu, K., Jia, Q., & Ding, X. (2019) · Bioscience Reports · doi:10.1042/bsr20181284 · Cited by 82
Lnc RNA MALAT 1/miR‐129 axis promotes glioma tumorigenesis by targeting SOX 2
Xiong, Z., Wang, L., Wang, Q., & Yuan, Y. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13667 · Cited by 79
Chen, W., Zhao, W., Zhang, L., Wang, L., Wang, J., Wan, Z., Hong, Y., & Yu, L. (2017) · Oncotarget · doi:10.18632/oncotarget.21693 · Cited by 78
Wang, Z., Katsaros, D., Biglia, N., Shen, Y., Fu, Y., Loo, L. W. M., Jia, W. P., Obata, Y., & Yu, H. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4839-2 · Cited by 77
Chang, J., Xu, W., Du, X., & Hou, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s164131 · Cited by 75
Sun, R., & Zhang, L. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.122 · Cited by 75
Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma
Dallmayer, M., Li, J., Ohmura, S., Rubío, R. A., Baldauf, M. C., Hölting, T. L. B., Musa, J., Knott, M. M. L., Stein, S., Cidre‐Aranaz, F., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1372-0 · Cited by 73
Yang, Z., Xie, Q., Chen, Z., Ni, H., Xia, L. P., Zhao, Q., Chen, Z., & Chen, P. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.7142 · Cited by 72
Wu, X., Li, R., Song, Q., Zhang, C., Jia, R., Han, Z., Zhou, L., Sui, H. X., Liu, X., Zhu, H., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1439-x · Cited by 72
The SINEB1 element in the long non-coding RNA Malat1 is necessary for TDP-43 proteostasis
Nguyen, T. M., Kabotyanski, E. B., Reineke, L. C., Shao, J., Xiong, F., Lee, J.-H., Dubrulle, J., Johnson, H. L., Stossi, F., Tsoi, P. S., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1176 · Cited by 69
Cardamone, G., Paraboschi, E. M., Soldà, G., Cantoni, C., Supino, D., Piccio, L. M., Duga, S., & Asselta, R. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy438 · Cited by 68
Zhou, Y., Shan, T., Ding, W., Hua, Z., Shen, Y., Lu, Z., Chen, B., & Dai, T. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26357 · Cited by 65
Tang, D., Yang, Z., Long, F., Luo, L., Yang, B., Zhu, R., Sang, X., & Cao, G. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.01.013 · Cited by 65
Chen, J., Liu, X., Xu, Y., Zhang, K., Huang, J., Pan, B., Chen, D., Cui, S., Song, H., Wang, R., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.005 · Cited by 64
Zhu, K., Ren, Q., & Zhao, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10253 · Cited by 64
Lin, N., Yao, Z., Xu, M., Chen, J., Lü, Y., Yuan, L., Zhou, S., Zou, X., & Xu, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1237-5 · Cited by 64
Gong, X., Zhu, Y., Hai-xia, C., Li, Y., & Ma, F. (2019) · Bioscience Reports · doi:10.1042/bsr20191103 · Cited by 62
Expression of MALAT1 in the peripheral whole blood of patients with lung cancer
Guo, F., Yu, F., Wang, J., Li, Y., Li, Y., LI, Z., & Zhou, Q. (2015) · Biomedical Reports · doi:10.3892/br.2015.422 · Cited by 61
Prognostic value of long noncoding RNAs in gastric cancer: a meta-analysis
Gao, S., Zhao, Z., Wu, R., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s169823 · Cited by 60
Zhao, L., Lou, G., Li, A., & Liu, Y. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11196 · Cited by 60
LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer
Liu, P., Li, X., Cui, Y., Chen, J., Li, C., Li, Q., Li, H., Zhang, X., & Zu, X. (2019) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmz112 · Cited by 59
He, B., Peng, F., Li, W., & Jiang, Y. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26823 · Cited by 56
Jia, Y., Guo, Y., Qiu, J., Qu, H., Qi, D., Song, P., Zhang, X., Wang, X., Xu, W., Dong, Y., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01547-5 · Cited by 54
Identification of drug‐regulated genes in osteosarcoma cells
Fellenberg, J., Dechant, M. J., Ewerbeck, V., & Mau, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11135 · Cited by 51
Yang, J., Yang, J., Sun, G., Hu, Y., Yang, J., Yang, J., Shi, Y., Liu, H., Li, C., Wang, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03161 · Cited by 50
Stone, J. K., Kim, J., Vukadin, L., Richard, A., Giannini, H. K., Lim, S., Tan, M., & Ahn, E.-Y. E. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006889 · Cited by 49
Zhao, Z.-B., Chen, F., & Bai, X.-F. (2019) · Yonsei Medical Journal · doi:10.3349/ymj.2019.60.8.727 · Cited by 48
Herrero, A. B., Quwaider, D., Corchete, L. A., Mateos, M., García‐Sánz, R., & Gutierrez, N. C. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15078 · Cited by 47
Arun, K., Arunkumar, G., Duraisamy, B., Chandramohan, S. M., Murugan, A. K., & Munirajan, A. K. (2018) · Oncotarget · doi:10.18632/oncotarget.24841 · Cited by 46
Shao, G., Zhao, Z., Zhao, W., Hu, G., Zhang, L., Li, W., Xing, C., & Zhang, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.11184 · Cited by 45
MALAT1 and BACH1 are prognostic biomarkers for triple-negative breast cancer
Liu, F., Xiao, X., Ou, X., Gao, G., Bazhabayi, M., & Zhang, K. (2019) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_282_19 · Cited by 44
MALAT1 affects ovarian cancer cell behavior and patient survival
Lin, Q., Guan, W., Ren, W., Zhang, L., Zhang, J., & Xu, G. (2018) · Oncology Reports · doi:10.3892/or.2018.6384 · Cited by 43
Li, M., Dong, C., Sun, B., Lei, H., Wang, Y., Gong, Y., Sun, L., & Sun, Z. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116946 · Cited by 42
Liu, M., Yang, P., Mao, G., Deng, J., Peng, G., Ning, X., Yang, H., & Sun, H. (2019) · International Journal of Surgery · doi:10.1016/j.ijsu.2019.11.004 · Cited by 40
Hao, Y., Yan, Z., Zhang, A., Hu, S., Wang, N., Luo, X., Ma, W., Zhang, T., & He, H. (2020) · Virus Research · doi:10.1016/j.virusres.2020.197907 · Cited by 40
Tiansheng, G., Junming, H., Xiaoyun, W., Peixi, C., Du, S., & Qianping, C. (2020) · PubMed · doi:10.22074/cellj.2020.6837 · Cited by 39
Zhou, L., Yang, D., Ou, L.-N., Xing-rong, G., & Wu, B. (2020) · Journal of Diabetes Research · doi:10.1155/2020/4729019 · Cited by 38
Dai, X., Liu, L., Liang, Z., Guo, K., Xu, S., & Wang, H. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.01.011 · Cited by 36
Chang, H.-L., Bamodu, O. A., Ong, J.-R., Lee, W., Yeh, C., & Tsai, J.-T. (2020) · Cells · doi:10.3390/cells9041020 · Cited by 36
Tani, H., Nakamura, Y., Ijiri, K., & Akimitsu, N. (2010) · PubMed · Cited by 34
Yuan, L.-T., Chang, J., Lee, H., Yang, Y., Su, S., Lin, C.-L., Yang, S.-F., & Chien, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091406 · Cited by 32
Du, M., Chen, W., Zhang, W., Tian, X., Wang, T., Wu, J., Gu, J., Zhang, N., Lü, Z., Qian, L., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.120 · Cited by 31
Wu, X., Wang, Y., Zhong, W., Cheng, H., & Tian, Z. (2020) · Medical Science Monitor · doi:10.12659/msm.922012 · Cited by 27
Quantitative Proteomics to Identify Nuclear RNA-Binding Proteins of Malat1
Scherer, M., Levin, M., Butter, F., & Scheibe, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031166 · Cited by 26
Gu, L.-N., Liu, J., Xu, D., & Lü, Y. (2019) · Medical Science Monitor · doi:10.12659/msm.915598 · Cited by 25
Lv, P., Yang, S., Liu, W., Qin, H., Tang, X., Wu, F., Liu, Z., Gao, H., & Liu, X. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13216 · Cited by 21
Lin, L., Li, H., Zhu, Y., He, S., & Ge, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8531 · Cited by 20
Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas
Argadal, Ö. G., Mutlu, M. B., Aksoy, S. A., Kocaelı, H., Tunca, B., Civan, M. N., Egelí, Ü., Çeçener, G., Bekâr, A., Taşkapılıoğlu, M. Ö., et al. (2019) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2019.4297 · Cited by 17
Diagnostic efficacy of long non-coding RNA MALAT-1 in human cancers: a meta-analysis study
Chen, Y., Xiao, Z., Hu, M., Luo, X., & Cui, Z. (2017) · Oncotarget · doi:10.18632/oncotarget.21013 · Cited by 10
Cited by
Stem cell-derived exosomes: emerging therapeutic opportunities for wound healing
Zhou, C., Zhang, B., Yang, Y., Jiang, Q., Li, T., Gong, J., Tang, H., & Zhang, Q. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03345-0 · Cited by 341
Metadata
- Authors
- Goyal, B., Yadav, S. R. M., Awasthee, N., Gupta, S., Kunnumakkara, A. B., & Gupta, S. C.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2021-04
- Volume
- 1875
- Issue
- 2
- Pages
- 188502
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3120607876
- Cited by
- 358
- References
- 130
- FWCI
- 21.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.